Clinical Trials
37 trialsA Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
SS1
Baylor College of Medicine
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
ToTem
University College, London
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
Dana-Farber Cancer Institute
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
University of Washington
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Stanford University
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Memorial Sloan Kettering Cancer Center
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
University of California, San Francisco
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
A Phase I Trial of ZIO-101 in Hematologic Cancers
Alaunos Therapeutics
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Daiichi Sankyo
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Healios K.K.
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
Case Comprehensive Cancer Center
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MS-275 in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Rutgers, The State University of New Jersey